Strand Therapeutics announced $153 million in Series B funding to advance its programmable mRNA therapeutics pipeline, led by STX-001, a novel therapy that expresses interleukin-12 (IL-12) directly from the tumor microenvironment. The company recently reported promising initial Phase 1 clinical data for patients with advanced solid tumors, demonstrating multiple RECIST responses including cases of complete response and complete metabolic response, multiple cases of prolonged disease stabilization, and a favorable safety profile in treatment-resistant patients.
Major Autoimmune and Oncology Investments
SetPoint Medical secured $140 million in private financing, comprising $25 million in the second tranche of its Series C financing and $115 million in its Series D financing. The proceeds will support commercialization of the SetPoint System, described as a first-of-its-kind neuroimmune modulation therapy for adults living with moderate-to-severe rheumatoid arthritis, as well as advancement of the company's pipeline in other autoimmune conditions.
ARTBIO closed a $132 million Series B financing to support advancement of its alpha radioligand therapy pipeline, including its lead program AB001 for metastatic castration-resistant prostate cancer through Phase II clinical trials. The company plans to rapidly advance its manufacturing network infrastructure to supply global clinical trials and commercialization.
Cell and Gene Therapy Platform Expansion
METiS Technologies completed its RMB 400 million ($55.7 million) Series D financing round to accelerate core strategic initiatives including automation upgrades to its proprietary platform, in-house pipeline development, expansion of global partnerships, and talent recruitment. The company launched the OpenCGT platform designed to address key challenges in precision nanodelivery, reduce costs and complexity, and enable clinical translation of next-generation cell and gene therapies. The platform bridges the gap between foundational research in leading academic institutions and major hospitals, and translational work by biotech firms. Its inaugural project enables AccurEdit Therapeutics to develop a liver-targeted CRISPR gene-editing therapy using mRNA-LNP delivery.
Reproductive Care and CRISPR Therapeutics
Gameto announced completion of a $44 million Series C financing round to complete the ongoing Phase 3 trial for its lead program, Fertilo, and file for regulatory approvals globally. The therapy uses engineered ovarian support cells derived from iPSCs to mature eggs outside the body, reducing the standard ovarian stimulation protocol from two weeks of daily hormone injections to 2-3 days. The Fertilo Phase 3 trial represents the first randomized, controlled, double-blind study evaluating ex vivo egg maturation.
SNIPR announced the close of a $40.6 million Series B raise to support development of a CRISPR-Cas therapy specifically targeting airway infections caused by Pseudomonas aeruginosa in people with cystic fibrosis. The funding will also enable advancement of a CRISPR-based microbial intervention designed to eliminate antibiotic resistance genes in humans across various bacterial species and environments, and further clinical development of SNIPR001 in patients with hematologic cancer, including the ongoing phase 1b trial.
Emerging Technologies and Specialized Therapeutics
Jocasta Neuroscience raised $35 million in Series A financing to support development of its lead asset, JN-0413, a proprietary formulation of the α-Klotho protein through Phase 1 development, including both Single Ascending Dose and Multiple Ascending Dose studies, with an IND submission planned for Q4 2026. The α-Klotho protein therapeutic targets cognitive decline in neurodegenerative diseases.
Maxwell Biosciences closed a $20 million financing round to support upcoming FDA clinical trials and advance AI-driven R&D for its Claromer drug candidates. Claromers are shelf-stable synthetic small molecules that mimic the human innate immune system to target and destroy viruses, bacteria, fungi and biofilms without harming healthy tissue. These compounds offer a broad-spectrum approach that preserves the body's natural microbial balance, addressing a key limitation of conventional antibiotics and antifungals.
Sava Technologies announced $19 million in Series A funding following promising clinical trial results to accelerate regulatory approval and commercialization of its next-generation wearable biosensor. The company developed a multi-molecule biosensor capable of detecting biomarkers just beneath the skin in real-time, powering their first product—a pain-free Continuous Glucose Monitor that delivers molecular insights to smartphones at a fraction of current alternatives' cost. Early results from the first 25 patients showed the proprietary technology delivered reliable, accurate glucose readings for up to 10 days of continuous wear.
Belhaven Biopharma closed an oversubscribed $10 million Series A financing round to complete clinical development and commercial manufacturing of Nasdepi and prepare for New Drug Application submission to the FDA. Nasdepi is positioned to be the first dry powder, needle-free, and heat-stable epinephrine therapy designed for emergency treatment of anaphylaxis to reach the market.
